← All Kineta, Inc/de filings

Kineta, Inc/de DEF 14A proxy statements

Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.

KANT
Kineta, Inc/de
DEFM14A: TuHURA Biosciences to Acquire Kineta in Strategic Cash and Stock Merger, Expanding Immuno-Oncology Pipeline
TuHURA Biosciences, Inc. has entered into a definitive agreement to acquire Kineta, Inc. in a cash and stock transaction, aiming to integrate Kineta's novel VISTA blocking immunotherapy and other assets to enhance its immuno-oncology pipeline.
KANT
Kineta, Inc/de
DEFA14A: TuHURA Biosciences and Kineta, Inc. Announce Non-Binding Letter of Intent for Potential Acquisition of KVA12123
TuHURA Biosciences and Kineta, Inc. have entered into a non-binding letter of intent for TuHURA to potentially acquire Kineta's KVA12123 VISTA inhibiting antibody.
KANT
Kineta, Inc/de
DEFA14A: Kineta, Inc. Sets Date for 2023 Annual Meeting, Outlines Proposals for Stockholder Vote
Kineta, Inc. announces its 2023 Annual Meeting to be held on June 7, 2023, with stockholders voting on director elections, auditor ratification, and executive compensation.
KANT
Kineta, Inc/de
DEF 14A: Kineta, Inc. Sets Date for 2024 Annual Stockholders Meeting
Kineta, Inc. announces its 2024 Annual Meeting of Stockholders to be held virtually on June 21, 2024, covering director elections, auditor ratification, and executive compensation advisory votes.